France
Sinnovial SAS is a biotechnology company founded in 2015, specializing in developing personalized medicine devices to improve the management of Chronic Inflammatory Rheumatisms (CIR) in Rheumatology, particularly rheumatoid arthritis and ankylosing spondylitis. The company's flagship product, Sinnotest®, aims to assist rheumatologists in optimizing the prescription of biotherapies.
The mission of Sinnovial SAS is to enhance the quality of life for patients by maximizing the success rate of their biotherapy treatment. The company endeavors to provide physicians with a real-time therapeutic orientation aid to optimize the selection of biotherapy, emphasizing the importance of "The right treatment, for the right patient, at the right time!"
Operating in the Biotechnology industry, Sinnovial SAS is focused on addressing unmet needs in rheumatology and improving patient outcomes. However, specific details regarding the company's headquarters, last investment, and investors are not available at this time.
